News

IntelGenx and Cary Pharma have previously entered into a collaborative agreement to jointly develop and commercialize CPI-300 using IntelGenx’s oral delivery technology. Under the terms of the collaborative

Mr Cotter spent 10 years as the vice president of operations for Closure Medical, a medical device company, acquired by Johnson & Johnson. Prior to Closure Medical, Mr

This financing round, which consists of two tranches, was led by new investor ProQuest Investments and includes the full pro rata participation of existing investors Apax Partners, Clarus

The MitraClip system is reported to be the first commercially available treatment option for non-surgical mitral valve repair for patients suffering from the effects of functional and degenerative

As part of the agreement, University of Pittsburgh Medical Center (UPMC) will extend the Sunquest system, already in 15 of its 20 hospitals, to additional sites. Additionally, after

One of the conditions to Uluru making any offer is that the outstanding debt of York shall be converted into ordinary shares of York prior to the closing

InSite Vision, a developer of new ocular pharmaceutical products, has reported that the Therapeutic Products Directorate of Health Canada has approved the company’s new drug submission for AzaSite

This molecular diagnostic tool helps to identify individuals at elevated risk for early heart attack. As part of the agreement, the test will be marketed by Labec Pharma

The FDA has stated that AstraZeneca did not provide adequate data to establish the appropriate dose or doses of the individual components of Symbicort – budesonide and formoterol